- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06332755
Studie för att utvärdera LB-LR1109 för behandling av solida tumörer (LB-LR1109)
En fas 1, först i människa, öppen etikett, multicenter, dosökningsstudie för att utvärdera säkerheten, tolerabiliteten, farmakokinetiken och farmakodynamiken hos LB-LR1109 för behandling av avancerade eller metastaserande solida tumörer
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and/or metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and/or metastatic NSCLC.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Rekrytering
- NEXT Oncology
-
Kontakt:
- Alexander Spirra
- Telefonnummer: 703-783-4508
- E-post: alexander.spira@usoncology.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
-
Age ≥18 years old at the time of signing the ICF.
-
(Phase 1a only) Participants must have 1 of the following histologically confirmed advanced or metastatic solid tumors with measurable or non-measurable disease as determined by RECIST v1.1,
- NSCLC, HNSCC, RCC, urothelial carcinoma, or malignant melanoma.
-
(Phase 1a only) Participants who have metastatic disease which has progressed during or after approved standard therapies or are intolerant to approved therapies, or for which the participant refuses or is ineligible for standard therapy.
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
-
Life expectancy ≥12 weeks.
-
Participants with adequate organ function
-
No potential for childbearing or agree to use adequate contraception
-
Ability to understand the study purpose and procedures and have the willingness to sign a written informed consent document.
-
(Phase 1b only ) Must have histologically confirmed advanced or metastatic NSCLC without actionable genomic alteration that have approved therapies in the location where the participant's live and with measurable disease as determined by RECIST v1.1
Key Exclusion Criteria:
- Clinically significant cardiac disease or cardiac failure.
- Untreated or unstable brain or central nervous system (CNS) metastases or Leptomeningeal disease
- Participants with any concurrent active malignancies
- Has received prior therapy targeting LILRB or immunoglobulin-like transcript pathway.
- History of life-threatening toxicity related to prior immune therapy
- Has not recovered to ≤ Grade 1 or baseline from AEs and/or complications from prior surgical intervention or any anti-cancer treatment before starting study treatment
- Participants must not have an active, known, or suspected autoimmune disease.
- Evidence of active infection requiring IV antibiotic treatment ≤7 days prior to initiation of study treatment therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry).
- Pregnant or lactating or expecting to conceive a child during the study or within 6 months after the last dose of study intervention.
- Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study intervention and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
- (Phase 1b only) Participants who were previously exposed to atezolizumab
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: fas 1a: Dosupptrapping / LB-LR1109 monoterapi
|
intravenous administration |
|
Experimentell: Fas 1b: Dosupptrappning / LB-LR1109 i kombination med Atezolizumab
|
intravenous administration |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Phase 1a: MTD and/or RP2D of LB-LR1109 as monotherapy in participants with advanced or metastatic solid tumors / Phase 1b: MTD and/or RP2D of LB-LR1109 as combination therapy with atezolizumab in participants with advanced or metastatic NSCLC
Tidsram: through study completion, an average of 1year
|
Number of participants with dose-limiting toxicities (DLTs) |
through study completion, an average of 1year
|
|
Phase 1a: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as monotherapy / Phase 1b: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year
|
Incidence, severity (assessed by NCI CTCAE v5.0), and causality of AEs |
through study completion, an average of 1year
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Phase 1a / 1b: Preliminary efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year
|
ORR(overall response rate) assessed by RECIST v1.1 (%) |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Antitumor efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year
|
PFS(Progression free survival) |
through study completion, an average of 1year
|
|
Phase 1a/1b: Antitumor efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year
|
OS (Overall survival) (months) |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Pharmacokinetic profile of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year
|
Cmax (Maximum serum drug concentration) |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Characterize PK of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year
|
Area under the concentration-time curve (AUC) 0-last |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Immunogenicity of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Tidsram: through study completion, an average of 1year
|
Number and percentage of participants with ADAs |
through study completion, an average of 1year
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Manliga urogenitala sjukdomar
- Njursjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Luftvägssjukdomar
- Neoplasmer efter histologisk typ
- Lungsjukdomar
- Neoplasmer i huvud och hals
- Neoplasmer, körtel och epitel
- Adenocarcinom
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Lungneoplasmer
- Hudsjukdomar
- Urologiska neoplasmer
- Carcinom
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Neoplasmer i njurarna
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Neuroendokrina tumörer
- Nevi och melanom
- Neoplasmer i huden
- Karcinom, skivepitel
- Hud- och bindvävssjukdomar
- Skivepitelcancer i huvud och hals
- Karcinom, njurcell
- Karcinom, icke-småcellig lunga
- Melanom
- Karcinom, övergångscell
- atezolizumab
Andra studie-ID-nummer
- LG-LRCL001
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .